Coronary artery disease (CAD) is one of the diseases with the highest morbidity and mortality, also the major public health problem worldwide. The Global Burden of Disease Study 2017 showed that the population of CAD had reached 110 million in 2016. And approximately 8.92 million died of CAD in this year alone. The most common manifestation of CAD is chronic stable angina (CSA) that makes patients suffer a lot. It’s also associated with increased risks of major adverse cardiovascular events, such as cardiovascular mortality, hospitalization for myocardial infarction, or heart failure. Currently, the aims of treatment of CSA are relieving of symptoms and preventing cardiovascular events. The major treatments include drug treatment (beta-receptor blockers, nitrates, calcium channel blockers and antiplatelet agents) and revascularization. However, in 2019 AHA Scientific Sessions, the ISCHEMIA study showed that heart procedures added to taking medicines and making lifestyle changes did not result in a reduced rate of heart attack or death compared with medicines and lifestyle changes alone. In addition, heart procedures did not reduce symptoms appreciably or improve the quality of life compared with medicines and lifestyle changes alone. This allows us to reconsider how to increase the clinical benefits of patients who have already received medication. In China, traditional Chinese medicine therapies are commonly applied in the treatment of CSA, including herbal medicine, acupuncture, Chinese patent medicine. Clinical studies have established that these therapies can alleviate chest pain, improve cardiac function and quality of life. Danlou tablet (DLT) is one of Chinese patent medicine, which approved by China Food and Drug Administration. It is originated from a TCM prescription named Gualou Xiebai Banxia Decoction recorded in Synopsis of Golden Chamber, which has been used to treat chest pain for more than 2000 years in China. Clinical studies have showed DLT could reduce the frequency and duration of angina pectoris, and improve cardiac function. Besides, several experiments have also validated the effects of DLT in decreasing inflammation, improving myocardial ischemia, protecting vascular endothelium and stabilizing vulnerable plaques. Although several clinical studies have reported the effectiveness of DLT for treating CSA, these studies have not yet been systematically summarized in high quality. Thus, the aims of this review are to examine the evidence of the effect and safety of DLT on CSA and provide recommendations on clinical practice.